Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) is frequently in the news as a global company focused on pet healthcare innovation, veterinary diagnostics, and software. News about IDEXX often highlights product launches, diagnostic advances, financial results, and corporate governance updates, reflecting its role in companion animal care, livestock and dairy health, and water safety.
Recent announcements include new diagnostic imaging and cancer testing capabilities. IDEXX has introduced the Vue DR50 Plus Digital Imaging System, described as its most advanced diagnostic imaging solution for veterinary practices, combining high-definition, AI-powered imaging with lower radiation doses compared with earlier IDEXX systems and other veterinary imaging solutions. The company has also reported expansions of its IDEXX Cancer Dx Panel and applications on the inVue Dx Cellular Analyzer, aimed at providing earlier insights and rapid, in-clinic answers for canine cancer cases.
Investors and veterinary professionals following IDXX news will also encounter quarterly earnings releases, where IDEXX discusses revenue growth, earnings per share, and performance across areas such as the Companion Animal Group, Water, and Livestock, Poultry and Dairy. Additional news items cover topics like CEO succession planning, board appointments, and participation in investor conferences.
This news page aggregates these types of updates so readers can review IDEXX’s latest disclosures on diagnostics, software, AI-enabled tools, telemedicine services, and financial performance. For anyone tracking IDXX stock, veterinary sector developments, or advances in animal health diagnostics, this feed provides a centralized view of the company’s publicly reported developments over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
IDEXX Laboratories (NASDAQ: IDXX) has announced the release date for its first quarter 2023 financial results, set for May 2, 2023, before the market opens. The company will hold an analyst conference call at 8:30 a.m. ET on the same day. Interested parties can access the live webcast and related financial documents via the IDEXX investors' website. An archived version of the call will be available after 1:00 p.m. ET for a year. IDEXX, a leader in pet healthcare innovation, serves customers in over 175 countries and employs nearly 11,000 people. The company focuses on improving veterinary diagnostics and ensuring the safety of food and water.
IDEXX Laboratories (NASDAQ: IDXX), a leader in pet healthcare innovation, will participate in two key conferences in early March 2023. On March 2 at 10:00 am EST, CFO Brian McKeon and SVP Michael Schreck will engage in a virtual fireside chat at the BofA Securities Animal Health Summit. Following this, on March 6 at 10:25 am EST, CEO Jay Mazelsky will present at the 44th Annual Raymond James Institutional Investors Conference. Both events will offer live audio webcasts accessible via the IDEXX website. An archived edition will also be available.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has released an empirical study highlighting ways to address capacity constraints in veterinary practices. The study, titled Finding the Time: Empowering Veterinary Teams to Get the Most Out of Every Day, introduces the Practice Productivity Index™, which identifies opportunities for practices to gain up to 2,000 hours per year. Key findings reveal that 82% of practices are struggling to hire staff, and 85% face technology integration issues. The study emphasizes that optimizing workflow, technology, and culture can significantly enhance productivity, ultimately supporting veterinary staff well-being.
IDEXX Laboratories reported a 3% revenue increase in Q4 2022, reaching $829 million, with 7% organic growth. The Companion Animal Group (CAG) saw a 4% reported and 8% organic revenue growth, driven by strong demand for diagnostic services. EPS rose 8% to $2.05. For 2023, IDEXX forecasts revenue between $3,590 million and $3,690 million, indicating 6.5%-9.5% growth. Expected EPS is $9.27 to $9.75, representing an increase of 16%-21%. Key growth factors include an expanded global premium instrument installed base and solid execution strategies.